717 related articles for article (PubMed ID: 31395068)
1. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.
Orth M; Metzger P; Gerum S; Mayerle J; Schneider G; Belka C; Schnurr M; Lauber K
Radiat Oncol; 2019 Aug; 14(1):141. PubMed ID: 31395068
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
[TBL] [Abstract][Full Text] [Related]
3. Molecular biology of adenocarcinoma of the pancreatic duct, current state and future therapeutic avenues.
Abbas S
Surg Oncol; 2013 Jun; 22(2):69-76. PubMed ID: 23415924
[TBL] [Abstract][Full Text] [Related]
4. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.
Tesfaye AA; Kamgar M; Azmi A; Philip PA
Expert Rev Anticancer Ther; 2018 Feb; 18(2):131-148. PubMed ID: 29254387
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
Montemagno C; Cassim S; De Leiris N; Durivault J; Faraggi M; Pagès G
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203923
[TBL] [Abstract][Full Text] [Related]
6. Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma.
Cinar P; Ko AH
J Natl Compr Canc Netw; 2014 Feb; 12(2):167-72. PubMed ID: 24586078
[TBL] [Abstract][Full Text] [Related]
7. Islets and pancreatic ductal adenocarcinoma - An opportunity for translational research from the 'Bench to the Bedside'.
Barreto SG; Michael MZ; Keating DJ
Pancreatology; 2020 Apr; 20(3):385-390. PubMed ID: 32057682
[TBL] [Abstract][Full Text] [Related]
8. Response assessment in pancreatic ductal adenocarcinoma: role of imaging.
Baliyan V; Kordbacheh H; Parakh A; Kambadakone A
Abdom Radiol (NY); 2018 Feb; 43(2):435-444. PubMed ID: 29243123
[TBL] [Abstract][Full Text] [Related]
9. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic and Predictive Factors for Pancreatic Adenocarcinoma].
Karásek P; Hermanová M
Klin Onkol; 2016; 29(5):336-341. PubMed ID: 27739311
[TBL] [Abstract][Full Text] [Related]
11. [Advances in immunotherapy of pancreatic ductal adenocarcinoma].
Yang JQ; Wei T; Chen YW; Bai XL; Liang TB
Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):396-400. PubMed ID: 28464583
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic ductal carcinoma: from the bench to the bedside.
Pezzilli R
JOP; 2006 Sep; 7(5):508-10. PubMed ID: 16998251
[No Abstract] [Full Text] [Related]
13. Multimodal treatment of resectable pancreatic ductal adenocarcinoma.
Silvestris N; Brunetti O; Vasile E; Cellini F; Cataldo I; Pusceddu V; Cattaneo M; Partelli S; Scartozzi M; Aprile G; Casadei Gardini A; Morganti AG; Valentini V; Scarpa A; Falconi M; Calabrese A; Lorusso V; Reni M; Cascinu S
Crit Rev Oncol Hematol; 2017 Mar; 111():152-165. PubMed ID: 28259290
[TBL] [Abstract][Full Text] [Related]
14. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
15. Locally advanced anaplastic pancreatic adenocarcinoma with initial response to FOLFIRINOX and rapid progression after five months.
Shinagare AB; Ramaiya NH; Bellizzi AM; Mayer RJ
Pancreatology; 2012; 12(1):35-8. PubMed ID: 22487471
[TBL] [Abstract][Full Text] [Related]
16. New Diagnostic and Therapeutic Aspects of Pancreatic Ductal Adenocarcinoma.
Mangge H; Niedrist T; Renner W; Lyer S; Alexiou C; Haybaeck J
Curr Med Chem; 2017; 24(28):3012-3024. PubMed ID: 28494747
[TBL] [Abstract][Full Text] [Related]
17. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.
Yeh R; Dercle L; Garg I; Wang ZJ; Hough DM; Goenka AH
Abdom Radiol (NY); 2018 Feb; 43(2):415-434. PubMed ID: 29143875
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.
Endo Y; Kitago M; Aiura K; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Nakano Y; Itano O; Fukada J; Masugi Y; Kitagawa Y
World J Surg Oncol; 2019 Aug; 17(1):145. PubMed ID: 31420046
[TBL] [Abstract][Full Text] [Related]
19. Health Disparities Impact Expected Treatment of Pancreatic Ductal Adenocarcinoma Nationally.
Lutfi W; Zenati MS; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Jul; 25(7):1860-1867. PubMed ID: 29691733
[TBL] [Abstract][Full Text] [Related]
20. Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas: The Cancer Immunity Cycle.
Kieler M; Unseld M; Bianconi D; Prager G
Pancreas; 2018 Feb; 47(2):142-157. PubMed ID: 29346215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
